U.S. Capital Markets Stock News

The AES Corporation’s Board of Directors recently declared a quarterly common stock dividend of US$0.17595 per share, payable on February 13, 2026 to shareholders of record at the close of business on January 30, 2026. Alongside this, an analyst upgrade has drawn attention to AES’s role in delivering greener, smarter energy solutions while continuing regular cash returns to shareholders. We’ll now examine how AES’s latest dividend declaration may influence its investment narrative,...

LegalZoom.com (LZ) drew fresh investor attention after renewing its partnership with Defy Ventures, a move that expands support for mental well being and entrepreneurship among formerly incarcerated individuals while reinforcing the company’s broader social impact strategy. See our latest analysis for LegalZoom.com. The renewed Defy Ventures partnership arrives as LegalZoom.com trades at $9.38, with a solid year to date share price return of 24.07 percent and a more modest 1 year total...

NXP Semiconductors (NXPI) has been drawing fresh attention as its shares climbed into the ex-dividend date, with management emphasizing a narrative of cyclical recovery despite recent dips in revenue and net income. See our latest analysis for NXP Semiconductors. That optimism is already showing up in the tape, with NXP’s share price at $227.95 after a strong recent run, a double digit year to date share price return, and a solid multi year total shareholder return profile suggesting momentum...

If you are wondering whether Vericel is a beaten down opportunity or a value trap at today’s price, you are exactly the kind of investor this breakdown is for. The stock is down around 10% over the last week, roughly flat over the past month, and still sitting on a steep YTD and 1 year decline despite being up strongly over 3 and 5 years. This makes the current setup look very different depending on your time horizon. Much of the recent share price action has been shaped by shifting...

In November 2025, Intuit Inc. announced that its SMB MediaLabs first-party small and mid-market business audience segments became available on The Trade Desk, broadening advertiser access to privacy-conscious, data-driven campaigns across connected TV, audio, display, and digital out-of-home channels. This move deepens Intuit’s role as a data partner for brands seeking verified SMB decision-makers, complementing analyst commentary that highlights ongoing product innovation and strong...

Burford Capital (NYSE:BUR) is back in the spotlight as investors reassess its huge bet on the Argentina YPF litigation, a single case that could meaningfully reshape the company’s earnings profile and valuation. See our latest analysis for Burford Capital. At around $9.29, Burford’s share price has suffered a sharp reset, with a roughly 30 percent 3 month share price return and weak year to date performance, even as its 3 year total shareholder return remains positive. This suggests momentum...

In recent days, Cadence Design Systems has drawn fresh attention after strong quarterly results, raised full-year guidance, and positive commentary on its financial health, alongside CEO Anirudh Devgan’s appearance at the UBS Global Technology and AI Conference 2025 in Scottsdale. Investors also took comfort from the resolution of earlier China-related sales concerns and a low, declining short interest level versus peers, which together point to improving confidence in the company’s...

From August 6 to October 31, 2025, Star Bulk Carriers completed a share repurchase of 462,476 shares, about 0.4% of its stock, for US$8.6 million under its previously announced buyback program. This latest tranche underlines management’s continued use of buybacks alongside dividends and debt reduction to reshape the capital structure and support per-share metrics. Next, we’ll examine how this completed buyback tranche fits into Star Bulk’s broader investment narrative around capital...

Wondering whether Coinbase Global at around $270 is still a smart way to play the crypto ecosystem, or if the easy money has already been made? You are not alone, and that is exactly what this breakdown will tackle. The stock is down about 1.1% over the last week and 15.5% over the last month. Yet it is still up 4.9% year to date and an eye catching 570.3% over three years, a pattern that suggests shifting risk appetite rather than a simple uptrend or downtrend. Recent moves have come...

In early December 2025, Atlassian Corporation announced that its core cloud apps, Jira, Confluence, and Jira Service Management, are now publicly listed on AWS Marketplace, enabling enterprises in more than 150 countries and over 15 currencies to procure and manage these tools directly through their AWS accounts. This expansion deepens Atlassian’s multi-year collaboration with AWS, aiming to speed up complex cloud migrations and unlock AI and security features that are only available in...

On December 5, 2025, activist investor Holdco Asset Management urged KeyCorp to halt acquisitions, prioritize share buybacks, overhaul its board, and replace Chairman and CEO Christopher Gorman, citing value destruction from the 2016 First Niagara deal and calling for an independent capital allocation committee. By openly contemplating a proxy contest or even a sale of KeyCorp to larger peers, Holdco has put unusual public pressure on the bank’s 200-year-old franchise and its current...

AbCellera Biologics (ABCL) just added another twist to its evolving story, as the board moved to replace long time auditor KPMG with Ernst and Young starting with the 2026 fiscal year. See our latest analysis for AbCellera Biologics. The auditor change lands amid a choppy stretch for the stock, with a roughly 24 percent 1 month share price return decline and a still negative 3 year total shareholder return, even though year to date and 1 year total shareholder returns have turned positive as...

HealthEquity (HQY) has been treading water lately, with the stock roughly flat over the past month after a modest 3 month climb. That makes this a good moment to revisit what is driving the story. See our latest analysis for HealthEquity. Over the past year, HealthEquity’s share price return has been slightly negative even as its multi year total shareholder return remains strong. This suggests that recent weakness may be more about shifting risk sentiment than fundamentals. If HealthEquity’s...

Federal Realty Investment Trust (FRT) has been drifting slightly this month, and that kind of quiet tape often hides useful signals about how investors are weighing its income profile against rising-rate worries. See our latest analysis for Federal Realty Investment Trust. At around a 10 percent year to date share price decline from 97.2 dollars, with a five year total shareholder return of roughly 33 percent, Federal Realty’s recent weakness looks more like momentum fading than a broken long...

LKQ (LKQ) has quietly slipped over the past year, with the stock down roughly 22% even as revenue and net income keep inching higher. That gap between fundamentals and share price is worth unpacking. See our latest analysis for LKQ. Recent swings have been more about sentiment than fundamentals, with a 1 year to date share price return of negative 18.7 percent and a 3 year total shareholder return of negative 39.9 percent signaling fading momentum despite steady earnings progress. If LKQ's...

Estée Lauder Companies (EL) just turned online perfume shopping into more of a conversation than a guess, debuting Jo Malone London’s AI powered Scent Advisor and nudging the stock higher as investors reassess its fragrance strategy. See our latest analysis for Estée Lauder Companies. The launch of Scent Advisor caps a strong rebound in sentiment, with a roughly 42 percent year to date share price return at a 105.13 dollars close, even as the five year total shareholder return remains sharply...

In recent weeks AbbVie has reported positive late-stage trial results for migraine drug atogepant, advanced oncology assets including PVEK for rare blood cancers, and secured Canadian reimbursement progress for ulcerative colitis therapy SKYRIZI. Together with new EPKINLY approvals and upcoming ASH hematology presentations, these updates underline AbbVie’s effort to broaden its portfolio beyond legacy immunology earnings. Next, we’ll examine how the atogepant Phase 3 migraine data and...

Dana (DAN) has quietly turned into a strong performer this year, with the stock up roughly 86% year to date despite softer annual revenue, as improving profitability reshapes how investors are valuing the business. See our latest analysis for Dana. That surge has come with some bumps, and the latest 1 day and 7 day share price returns of negative 4.15% and negative 6.29% suggest a breather after big gains. At the same time, a 72.72% 1 year total shareholder return still points to strong,...

Earlier this week, TD Cowen met with Tapestry’s leadership and reaffirmed confidence after record first-quarter fiscal 2026 results, highlighting Coach’s strong revenue growth and a shift toward 65% evergreen products that support better inventory management and product breadth. The firm also emphasized progress under the “One Coach” strategy, while flagging Kate Spade as a longer-term turnaround, underscoring the company’s reliance on its flagship brand for current momentum. We’ll now...

Copart (CPRT) has quietly slid over the past few months, with the stock down about 8% for the month and roughly 20% in the past 3 months, despite steady revenue and earnings growth. See our latest analysis for Copart. Zooming out, that recent slide sits within a tougher stretch, with the share price down sharply year to date even as the three and five year total shareholder returns are still comfortably positive. This suggests long term momentum has not fully broken. If Copart’s pullback has...

Wondering if Progyny is still a smart buy after its big run, or if you have already missed the window? This breakdown will help you decide whether the current price really matches the company’s long term potential. Despite a choppy last week with the share price down 8.9%, Progyny is still up 27.2% over the last month, 35.5% year to date, and 62.7% over the past year, even though 3 and 5 year returns remain in the red. Recent gains have come as investors refocus on structural demand for...

In recent days, Bank of America has shifted its wealth management stance by allowing advisers to recommend a 1%–4% portfolio allocation to digital assets and beginning research coverage of several spot bitcoin ETFs, reversing its previous prohibition on crypto advice. This policy change positions the bank more directly in the growing market for regulated crypto exposure, aligning its wealth platform with evolving client demand and competitors’ digital asset offerings. With this new crypto...

McEwen (NYSE:MUX) just released fresh high grade drill results from Froome West in Ontario, extending gold mineralization both vertically and to the west, and that is exactly what has the stock in focus. See our latest analysis for McEwen. That operational momentum helps explain why McEwen’s recent 90 day share price return of 38.32 percent and year to date share price return of 127.24 percent look so strong, reinforcing a powerful three year total shareholder return of 243.77 percent. If...

Spyre Therapeutics (SYRE) drew fresh attention after reporting Phase 1 data that pointed to encouraging safety and activity signals for its investigational IBD antibodies, along with earnings per share that topped expectations. See our latest analysis for Spyre Therapeutics. Those upbeat trial results and recent conference visibility seem to be feeding into strong momentum, with the share price up sharply on a 30 day and 90 day basis and a hefty three year total shareholder return, though...